Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Jiangsu Hengrui Medicine Co., Ltd. (600276.SS)
CNY54.82
-0.93 (-1.67%)
CN SHH Healthcare Drug Manufacturers - General
Address
38 Huanghe Rd Eco & Tech Dev Park 222000
Lianyungang, CN
Lianyungang, CN
CEO
Piao Yang Sun
Website
hrs.com.cn
IPO
2000-10-18
ISIN CNE0000014W7
Also trades on
Hong Kong Stock Exchange · 1276.HK (HKD)
Shanghai Stock Exchange · 600276.SS (CNY)
Description
Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical firm engaged in the full spectrum of pharmaceutical operations, from the initial discovery and development of medications to their manufacturing and worldwide distribution. The company is actively advancing a substantial pipeline of drug candidates, which includes Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403. These prospective treatments are aimed at a diverse range of medical conditions, primarily focusing on oncology, metabolic disorders, pain management, and autoimmune diseases, among others. The enterprise was founded in 1970 and maintains its corporate headquarters in Lianyungang, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY54.82
-0.93 (-1.67%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
85M
Beta
0.12
Float Shares
3.77B
Free Float %
59.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +4.56% | +0.36% | -6.85% | -11.26% | -19.15% | -15.75% | -8.31% | +3.93% | -30.21% | +333.05% | +17,578.14% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
54.82
DCF (Unlevered)
63.11
+15.1%
DCF (Levered)
88.26
+61.0%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
97% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 15 | 0 |
| Buy | 15 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
29.45
Safe zone
Piotroski F-Score
5 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - General: +6.6%+12.3% ★ Q1'26: +13.0% (vs Q1'25)
-
EPS growth Drug Manufacturers - General: +18.2%+18.0% Q1'26: +16.7% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - General: +36.0%+30.6% ★ Q1'26: +1.0% (vs Q1'25)
-
EBIT margin Drug Manufacturers - General: +19.4%+25.5% ★ Q1'26: +30.7% (vs Q1'25)
-
ROIC Drug Manufacturers - General: +10.2%+32.8% ★ Q1'26: +37.8% (vs Q1'25)
-
Share dilution Drug Manufacturers - General: +0.0%+2.7% Q1'26: +5.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×0.10× ★ Q1'26: 0.01× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 19 Rev. Ana. 21 EPS Ana. |
Dec 2027 19 Rev. Ana. 18 EPS Ana. |
Dec 2028 16 Rev. Ana. 14 EPS Ana. |
Dec 2029 15 Rev. Ana. 8 EPS Ana. |
Dec 2030 15 Rev. Ana. 12 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
9.32B
est: 9.32B (+0.0%)
|
11.09B
est: 11.11B (-0.1%)
|
13.84B
est: 13.45B (+2.9%)
|
17.42B
est: 17.12B (+1.7%)
|
23.29B
est: 23.45B (-0.7%)
|
27.73B
est: 28.79B (-3.7%)
|
25.91B
est: 28.40B (-8.8%)
|
21.28B
est: 22.07B (-3.6%)
|
22.82B
est: 25.25B (-9.6%)
|
27.98B
est: 27.67B (+1.1%)
|
31.43B
est: 32.84B (-4.3%)
|
36.04B
35.36B – 37.13B
+9.7% YoY
|
41.77B
40.20B – 45.60B
+15.9% YoY
|
48.96B
48.81B – 49.11B
+17.2% YoY
|
67.82B
65.86B – 72.10B
+38.5% YoY
|
84.34B
81.91B – 89.67B
+24.4% YoY
|
| EBITDA |
2.64B
est: 1.95B (+35.3%)
|
3.10B
est: 2.32B (+33.4%)
|
3.89B
est: 2.81B (+38.5%)
|
4.44B
est: 3.58B (+24.0%)
|
6.12B
est: 4.90B (+24.8%)
|
6.72B
est: 6.02B (+11.6%)
|
4.26B
est: 5.94B (-28.2%)
|
3.60B
est: 4.61B (-22.0%)
|
4.84B
est: 5.49B (-11.9%)
|
7.19B
est: 6.02B (+19.5%)
|
8.96B
est: 7.15B (+25.4%)
|
7.84B
7.69B – 8.08B
+9.7% YoY
|
9.09B
8.75B – 9.92B
+15.9% YoY
|
10.65B
10.62B – 10.69B
+17.2% YoY
|
14.76B
14.33B – 15.69B
+38.5% YoY
|
18.35B
17.82B – 19.51B
+24.4% YoY
|
| EBIT |
2.41B
est: 1.73B (+39.3%)
|
2.84B
est: 2.06B (+37.7%)
|
3.58B
est: 2.50B (+43.0%)
|
4.06B
est: 3.18B (+27.5%)
|
5.50B
est: 4.36B (+26.2%)
|
6.27B
est: 5.35B (+17.1%)
|
3.76B
est: 5.28B (-28.7%)
|
3.06B
est: 4.10B (-25.4%)
|
4.18B
est: 4.84B (-13.7%)
|
6.48B
est: 5.31B (+22.0%)
|
8.02B
est: 6.30B (+27.3%)
|
6.91B
6.78B – 7.12B
+9.7% YoY
|
8.01B
7.71B – 8.74B
+15.9% YoY
|
9.39B
9.36B – 9.42B
+17.2% YoY
|
13.00B
12.63B – 13.82B
+38.5% YoY
|
16.17B
15.70B – 17.19B
+24.4% YoY
|
| Net Income |
2.17B
est: 2.19B (-0.9%)
|
2.59B
est: 2.59B (-0.2%)
|
3.22B
est: 3.20B (+0.6%)
|
4.07B
est: 3.96B (+2.5%)
|
5.33B
est: 5.23B (+1.8%)
|
6.33B
est: 6.36B (-0.5%)
|
4.53B
est: 6.15B (-26.3%)
|
3.91B
est: 4.12B (-5.3%)
|
4.30B
est: 5.43B (-20.7%)
|
6.34B
est: 6.52B (-2.9%)
|
7.71B
est: 8.67B (-11.1%)
|
9.28B
6.40B – 10.46B
+7.1% YoY
|
10.93B
8.50B – 12.83B
+17.7% YoY
|
13.48B
11.18B – 18.40B
+23.3% YoY
|
21.26B
20.47B – 23.01B
+57.8% YoY
|
26.69B
25.69B – 28.88B
+25.5% YoY
|
| SGA |
5.36B
est: 4.13B (+29.8%)
|
6.61B
est: 4.92B (+34.3%)
|
6.40B
est: 5.96B (+7.2%)
|
8.11B
est: 7.59B (+6.9%)
|
10.78B
est: 10.40B (+3.7%)
|
12.88B
est: 12.77B (+0.9%)
|
12.24B
est: 12.59B (-2.8%)
|
9.68B
est: 9.79B (-1.1%)
|
9.98B
est: 10.76B (-7.2%)
|
10.86B
est: 11.79B (-7.8%)
|
11.84B
est: 13.99B (-15.4%)
|
15.35B
15.06B – 15.81B
+9.7% YoY
|
17.79B
17.12B – 19.42B
+15.9% YoY
|
20.85B
20.79B – 20.92B
+17.2% YoY
|
28.88B
28.05B – 30.71B
+38.5% YoY
|
35.92B
34.89B – 38.19B
+24.4% YoY
|
| EPS |
0.34
est: 0.35 (-1.7%)
|
0.41
est: 0.41 (+0.2%)
|
0.50
est: 0.50 (-0.9%)
|
0.64
est: 0.63 (+2.3%)
|
0.84
est: 0.83 (+1.7%)
|
1.00
est: 1.00 (-0.3%)
|
0.71
est: 0.97 (-26.8%)
|
0.61
est: 0.65 (-6.3%)
|
0.68
est: 0.86 (-21.1%)
|
1.00
est: 0.98 (+2.0%)
|
1.19
est: 1.30 (-8.7%)
|
1.41
0.98 – 1.61
+8.4% YoY
|
1.69
1.31 – 1.97
+19.3% YoY
|
2.05
1.72 – 2.83
+21.4% YoY
|
3.27
3.14 – 3.53
+59.6% YoY
|
4.10
3.95 – 4.44
+25.5% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-28 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-27 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-26 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-25 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-22 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-21 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-20 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-19 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-18 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-15 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-14 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-13 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-12 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-08 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-06 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-04-30 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-22 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | B | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | B | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-15 | B+ | 3/5 | 5/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
6.09B
OE per share TTM
0.92
Owner's Yield
1.84%
Maintenance CapEx ratio
21.00%
Maint CapEx / Avg PPE
24.1%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
396.2K
Shares Outstanding
6.38B
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Cheng Liao | Deputy General Manager | — | male |
| Feng He | Deputy General Manager | — | male |
| Hong Bin Dai | Executive Deputy Chairman of the Board | — | male |
| Jie Ping Sun | Senior Vice President & Executive Director | — | male |
| Kin Chun Lau | Chief Financial Officer | — | male |
| Lian Shan Zhang | Executive Vice President & Executive Director | — | — |
| Ningjun Jiang | Executive Vice President, Chief Strategy Officer & Executive Director | — | — |
| Piao Yang Sun | Executive Chairman of the Board | — | male |
| Xiao Han Liu | Board Secretary | — | female |
| Ya Ping Shen | Deputy General Manager | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 600276.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
